Findings

What do systematic reviews say?

25 questions · 25 findings · 4 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 15 · 60%Low 4 · 16%Moderate 6 · 24%High 0 · 0%

CHLORPROMAZINE vs Clotiapine

Mental state: 1a. General symptoms ‐ average change (PANSS, short term) · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus clotiapine for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Very low

CHLORPROMAZINE vs Clotiapine

Mental state: 2c. Specific ‐ average change score for negative symptoms (PANSS ‐ negative short term) · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus clotiapine for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

CHLORPROMAZINE vs Clotiapine

Adverse effects: incidence of serious adverse effects. Movement disorders ‐ dyskinesia ‐short‐term · patients with schizophrenia

It is very uncertain whether chlorpromazine changes adverse effects: incidence of serious adverse effects. Movement… compared with clotiapine (very low certainty).

1 finding from 1 review

Chlorpromazine versus clotiapine for schizophrenia 2017 · Cochrane Headline outcomes only
RR 3 [0.13, 71.15]
1 study · 68 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia

CHLORPROMAZINE may leads to higher no significant clinical response: short term (up to 6 months) compared with OLANZAPINE (low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 2.34 [1.37, 3.99]
3 studies · 204 participants
Low

CHLORPROMAZINE vs RISPERIDONE

QoL · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

CHLORPROMAZINE vs RISPERIDONE

Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.21 [0.01, 4.11]
1 study · 41 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in no significant clinical response: short term (up to 6 months) compared with QUETIAPINE (moderate certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.93 [0.81, 1.06]
28 studies · 3241 participants
Moderate

CHLORPROMAZINE vs QUETIAPINE

Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 548 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

CHLORPROMAZINE may leads to higher adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with QUETIAPINE (low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 8.03 [4.78, 13.51]
8 studies · 644 participants
Low

CHLORPROMAZINE vs QUETIAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.04 [0.77, 1.41]
12 studies · 1223 participants
Moderate

CHLORPROMAZINE vs OLANZAPINE

Mental state: General ‐ average endpoint score (BPRS, high score = poor) ‐ medium term ( · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 245 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 34.47 [4.79, 248.3]
2 studies · 298 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Health‐related quality of life (physical) · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.69 [0.45, 6.4]
3 studies · 139 participants
Very low

CHLORPROMAZINE vs RISPERIDONE

No significant clinical response ‐ short term (up to 6 months) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in no significant clinical response ‐ short term (up to 6 months) compared with RISPERIDONE (low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.84 [0.53, 1.34]
7 studies · 475 participants
Low

CHLORPROMAZINE vs RISPERIDONE

Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 247 participants
Very low

CHLORPROMAZINE vs RISPERIDONE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with RISPERIDONE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.7 [0.85, 3.4]
3 studies · 235 participants
Very low

CHLORPROMAZINE vs RESERPINE

Global state: not improved ‐ short‐term GAF · patients with schizophrenia

CHLORPROMAZINE may leads to lower global state: Not improved (short term) compared with RESERPINE (low certainty).

1 finding from 1 review

Chlorpromazine versus reserpine for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.75 [0.62, 0.92]
6 studies · 781 participants
Low

CHLORPROMAZINE vs RESERPINE

Mental state: Not improved (paranoid distortion) Multidimentional Scale for Rating Psychiatric Patients (short term) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes mental state: Not improved (paranoid distortion) Multidimentional… compared with RESERPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus reserpine for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.33 [0.62, 2.89]
1 study · 19 participants
Very low